BLUENERGIES LTD (BLU.CA) Stock News
TSX:BLU - Toronto Stock Exchange - CA0959221007 - Common Stock - Currency: CAD
BLU.CA Latest News, Press Relases and Analysis
All
Press Releases
2 years ago - BELLUS Health Inc.
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
Mentions: BLU
2 years ago - BELLUS Health Inc.
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
2 years ago - BELLUS Health Inc.
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
Mentions: BLU
2 years ago - BELLUS Health Inc.
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
2 years ago - Bloomberg
GSK to Buy Bellus for $2 Billion to Gain Cough Medicine
GSK Plc agreed to buy Canadian biotech Bellus Health Inc. for a total equity value of about $2 billion to bolster its pipeline of experimental medicines.
2 years ago - BELLUS Health Inc.
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
Mentions: BLU
2 years ago - BELLUS Health Inc.
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
Mentions: BLU
2 years ago - BELLUS Health Inc.
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
Mentions: BLU
2 years ago - BELLUS Health Inc.
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
Mentions: BLU
2 years ago - BELLUS Health Inc.
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
Mentions: BLU
3 years ago - BELLUS Health Inc.
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Participate in the William Blair Biotech Focus Conference
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Participate in the Jefferies Healthcare Conference
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
Mentions: BLU
3 years ago - BELLUS Health Inc.
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
Mentions: BLU
4 years ago - BELLUS Health Inc.
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
Mentions: BLU
4 years ago - BELLUS Health Inc.
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
Mentions: BLU
4 years ago - BELLUS Health Inc.
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
Mentions: BLU
4 years ago - BELLUS Health Inc.
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
Mentions: BLU
4 years ago - BELLUS Health Inc.
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights
Mentions: BLU
4 years ago - BELLUS Health Inc.
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
Mentions: BLU